Table of Content

1. Key Insights


2. Executive Summary of Oral Mucositis


3. SWOT Analysis of Oral Mucositis


4. Oral Mucositis: Market Share (%) Distribution Overview at a Glance: By Country


5. Epidemiology and Market Methodology


6. Oral Mucositis: Disease Background and Overview

6.1.?? Introduction

6.1.1.?? Signs and Symptoms of Oral Mucositis

6.1.2.?? Risk Factors and Causes of Oral Mucositis

6.1.3.?? Pathogenesis of Oral Mucositis

6.1.4.?? Course of Oral Mucositis

6.1.5.?? Genetics of Oral Mucositis

6.1.6.?? Complications of Oral Mucositis


7. Diagnosis of Oral Mucositis

7.1.1.?? Medical history for Oral Mucositis

7.1.2.?? Grades of Oral Mucositis


8. Epidemiology and Patient Population

8.1.?? Epidemiology Key Findings

8.2.?? Assumptions and Rationale: 7MM


9. Epidemiology Scenario: 7MM

9.1.?? Total Incident Cases of Oral Mucositis in the 7MM

9.2.?? Grade-specific Incident Cases of Oral Mucositis in the 7MM

9.3.?? Treated Cases of Oral Mucositis in the 7MM


10. The United States Epidemiology

10.1. Total Incident Cases of Oral Mucositis in the United States

10.2. Grade-specific Incident Cases of Oral Mucositis in the United States

10.3. Treated Cases of Oral Mucositis in the United States


11. EU-5 Epidemiology

11.1. Germany

11.1.1.? Total Incident Cases of Oral Mucositis in Germany

11.1.2.? Grade-specific Incident Cases of Oral Mucositis in Germany

11.1.3.? Treated Cases of Oral Mucositis in Germany

11.2. France

11.2.1.? Total Incident Cases of Oral Mucositis in France

11.2.2.? Grade-specific Incident Cases of Oral Mucositis in France

11.2.3.? Treated Cases of Oral Mucositis in France

11.3. Italy

11.3.1.? Total Incident Cases of Oral Mucositis in Italy

11.3.2.? Grade-specific Incident Cases of Oral Mucositis in Italy

11.3.3.? Treated Cases of Oral Mucositis in Italy

11.4. Spain

11.4.1.? Total Incident Cases of Oral Mucositis in Spain

11.4.2.? Grade-specific Incident Cases of Oral Mucositis in Spain

11.4.3.? Treated Cases of Oral Mucositis in Spain

11.5. The United Kingdom

11.5.1.? Total Incident Cases of Oral Mucositis in the United Kingdom

11.5.2.? Grade-specific Incident Cases of Oral Mucositis in the United Kingdom

11.5.3.? Treated Cases of Oral Mucositis in the United Kingdom

11.6. Japan Epidemiology

11.6.1.? Total Incident Cases of Oral Mucositis in Japan

11.6.2.? Grade-specific Incident Cases of Oral Mucositis in Japan

11.6.3.? Treated Cases of Oral Mucositis in Japan


12. Current Treatment Practices: Oral Mucositis

12.1. Treatment Algorithm of Oral Mucositis

12.1.1.? Pain Control

12.1.2.? Palliation of dry mouth

12.1.3.? Nutritional Support

12.1.4.? Oral Decontamination

12.1.5.? Cryotherapy

12.1.6.? Low-level laser therapy

12.1.7.? Growth Factors

12.1.8.? Antioxidants and Anti-inflammatory agents


13. Prevention of Oral Mucositis


14. Guidelines of Oral Mucositis

14.1. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

14.2. ESMO Clinical Practice Guidelines for Oral Mucositis (Modified from MASCC/ISOO Clinical Practice Guidelines for Oral Mucositis)

14.3. American Society of Clinical Oncology (ASCO) Guidelines for Oral Mucositis

14.4. National Comprehensive Cancer Network (NCCN) Task Force Recommendations for the Prevention and Management of Mucositis in Cancer Care

14.5. Pediatric Guidelines of NHS for Oral Mucositis

14.6. Mouth care guidance and support in cancer and palliative care - UK Oral Mucositis in Cancer Group


15. Unmet Needs


16. Patient Journey of Oral Mucositis


17. Key Endpoints in Oral Mucositis Clinical Trials


18. Marketed Therapies

18.1. Kepivance (Palifermin): Amgen/ Swedish Orphan Biovitrum

18.1.1.? Product Description

18.1.2.? Regulatory Milestones

18.1.3.? Other Developmental Activities

18.1.4.? Pivotal Clinical Trials

18.2. MuGard: Access Pharmaceuticals

18.2.1.? Product Description

18.2.2.? Regulatory Milestones

18.2.3.? Other Developmental Activities

18.2.4.? Pivotal Clinical Trials

18.3. Chemo Mouthpiece: Chemo Mouthpiece/ Aurora BioScience

18.3.1.? Product Description

18.3.2.? Pivotal Clinical Trial

18.3.3.? Ongoing Current Pipeline Activity

18.4. Episil: Camurus

18.4.1.? Product Description

18.4.2.? Regulatory Milestones

18.4.3.? Other Developmental Activities

18.4.4.? Pivotal Clinical Trial


19. Emerging Therapies

19.1. Brilacidin: Innovation Pharmaceuticals

19.1.1.? Product Description

19.1.2.? Other Developmental Activities

19.1.3.? Clinical Development

19.1.4.? Safety and Efficacy

19.2. EC-18: Enzychem Lifesciences Corporation

19.2.1.? Product Description

19.2.2.? Other Developmental Activities

19.2.3.? Clinical Developmental Activities

19.3. Cooral System: BrainCool

19.3.1.? Product Description

19.3.2.? Other Developmental Activities

19.3.3.? Clinical Developmental Activities

19.3.4.? Safety and Efficacy

19.4. CareMin650: NeoMedLight

19.4.1.? Product Description

19.4.2.? Other Developmental Activities

19.4.3.? Clinical Developmental Activities

19.5. Validive (Clonidine Lauriad): Monopar Therapeutics

19.5.1.? Product Description

19.5.2.? Other Developmental Activities

19.5.3.? Clinical Developmental Activities

19.5.4.? Safety and Efficacy

19.6. MuReva Phototherapy System: MuReva (Lumitex)

19.6.1.? Product Description

19.6.2.? Other Developmental Activities

19.6.3.? Clinical Developmental Activities

19.7. RRx-001: EpicentRx/Prothex Pharma

19.7.1.? Product Description

19.7.2.? Other Developmental Activities

19.7.3.? Clinical Developmental Activities

19.7.4.? Safety and Efficacy

19.8. SGX942: Soligenix

19.8.1.? Product Description

19.8.2.? Other Developmental Activities

19.8.3.? Clinical Development

19.8.4.? Safety and Efficacy

19.9. Avasopasem (GC4419): Galera Therapeutics

19.9.1.? Product Description

19.9.2.? Other Developmental Activities

19.9.3.? Clinical Development

19.9.4.? Safety and Efficacy

20. Oral Mucositis: Seven Major Market Analysis

20.1. Key Findings

20.2. Market Outlook: 7MM

21. 7MM Market Size

21.1. Total Market Size of Oral Mucositis in the 7MM

21.2. Total Market size of Oral Mucositis by Therapies in the 7MM

22. The United States Market Size

22.1. Total Market size of Oral Mucositis in the United States

23. EU-5 Market Size

23.1. Germany Market Size

23.1.1.? Total Market size of Oral Mucositis in Germany

23.2. France Market Size

23.2.1.? Total Market size of Oral Mucositis in France

23.3. Italy Market Size

23.3.1.? Total Market size of Oral Mucositis in Italy

23.4. Spain Market Size

23.4.1.? Total Market size of Oral Mucositis in Spain

23.5. The United Kingdom Market Size

23.5.1.? Total Market size of Oral Mucositis in the United Kingdom

23.6. Japan Market Size

23.6.1.? Total Market size of Oral Mucositis in Japan

24. Market Access and Reimbursement of Oral Mucositis Therapies

24.1. Patient Assistance Program

24.2. Reimbursement Management

25. Market Drivers of Oral Mucositis

26. Market Barriers of Oral Mucositis

27. Appendix

27.1. Bibliography

27.2. Report Methodology

28. DelveInsight Capabilities

29. Disclaimer

30. About DelveInsight



List of Figures


Figure 1: Oral Mucositis SWOT Analysis

Figure 2: Epidemiology and Market Methodology

Figure 3: Oral Mucositis

Figure 4: Signs and Symptoms

Figure 5: Risk factors of Oral Mucositis

Figure 6: Pathogenesis of Oral Mucositis

Figure 7: Cytokines responsible at different stages of Oral Mucositis

Figure 8: Severe oral ulcerations

Figure 9: Global Heat Map of All Cancers

Figure 10: Total Incident Cases of Oral Mucositis in the 7MM (2018–2030)

Figure 11: Grade-specific Incident Cases of Oral Mucositis in the 7MM (2018–2030)

Figure 12: Treated Cases of Oral Mucositis in the 7MM (2018–2030)

Figure 13: Total Incident Cases of Oral Mucositis in the United States (2018–2030)

Figure 14: Grade-specific Incident Cases of Oral Mucositis in the United States (2018–2030)

Figure 15: Treated Cases of Oral Mucositis in the United States (2018–2030)

Figure 16: Total Incident Cases of Oral Mucositis in Germany (2018–2030)

Figure 17: Grade-specific Incident Cases of Oral Mucositis in Germany (2018–2030)

Figure 18: Treated Cases of Oral Mucositis in Germany (2018–2030)

Figure 19: Total Incident Cases of Oral Mucositis in France (2018–2030)

Figure 20: Grade-specific Incident Cases of Oral Mucositis in France (2018–2030)

Figure 21: Treated Cases of Oral Mucositis in France (2018–2030)

Figure 22: Total Incident Cases of Oral Mucositis in Italy (2018–2030)

Figure 23: Grade-specific Incident Cases of Oral Mucositis in Italy (2018–2030)

Figure 24: Treated Cases of Oral Mucositis in Italy (2018–2030)

Figure 25: Total Incident Cases of Oral Mucositis in Spain (2018–2030)

Figure 26: Grade-specific Incident Cases of Oral Mucositis in Spain (2018–2030)

Figure 27: Treated Cases of Oral Mucositis in Spain (2018–2030)

Figure 28: Total Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Figure 29: Grade-specific Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Figure 30: Treated Cases of Oral Mucositis in the United Kingdom (2018–2030)

Figure 31: Total Incident Cases of Oral Mucositis in Japan (2018–2030)

Figure 32: Grade-specific Incident Cases of Oral Mucositis in Japan (2018–2030)

Figure 33: Treated Cases of Oral Mucositis in Japan (2018–2030)

Figure 34: Treatment Algorithm of Oral Mucositis

Figure 35: Approach to assessing risk of mucositis and prevention of oral mucositis

Figure 36: Unmet needs

Figure 37: Chemo Mouthpiece

Figure 38: Mechanism of EC-18

Figure 39: Mechanism of SGX942

Figure 40: Market Size of Oral Mucositis in the 7MM, in USD Million (2018–2030)

Figure 41: Market Size of Oral Mucositis in the 7MM by Therapy, in USD Million (2018–2030)

Figure 42: Total Market Size of Oral Mucositis in the United States, in USD Million (2018–2030)

Figure 43: Market Size of Oral Mucositis in the United States by Therapy, in USD Million (2018–2030)

Figure 44: Total Market Size of Oral Mucositis in Germany, in USD Million (2018–2030)

Figure 45: Market Size of Oral Mucositis in Germany by Therapies, in USD Million (2018–2030)

Figure 46: Total Market Size of Oral Mucositis in France, in USD Million (2018–2030)

Figure 47: Market Size of Oral Mucositis in France by therapies, in USD Million (2018–2030)

Figure 48: Total Market Size of Oral Mucositis in Italy, in USD Million (2018–2030)

Figure 49: Market Size of Oral Mucositis in Italy by Therapies, in USD Million (2018–2030)

Figure 50: Total Market Size of Oral Mucositis in Spain, in USD Million (2018–2030)

Figure 51: Market Size of Oral Mucositis in Spain by therapies, in USD Million (2018–2030)

Figure 52: Total Market Size of Oral Mucositis in the United Kingdom, in USD Million (2018–2030)

Figure 53: Market Size of Oral Mucositis in the United Kingdom by Therapies, in USD Million (2018–2030)

Figure 54: Total Market Size of Oral Mucositis in Japan, in USD Million (2018–2030)

Figure 55: Market Size of Oral Mucositis in Japan by Therapy, in USD Million (2018–2030)

Figure 56: Market Drivers

Figure 57: Market Barriers


List of Tables


Table 1: Summary of Oral Mucositis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Differential diagnosis of Oral Mucositis

Table 3: WHO oral mucositis scale/common toxicity criteria

Table 4: National Cancer Institute Common Terminology Criteria (NCI CTC) Grading of the severity of adverse events secondary to chemotherapy and radiotherapy toxicity.

Table 5: Radiation Therapy Oncology Group Scale

Table 6: Radiation Therapy Oncology Group and European Organisation for Research and Treatment of Cancer (RTOG/EORTC) Scale

Table 7: Oral assessment guide for children and young people

Table 8: Total Incident Cases of Oral Mucositis in the 7MM (2018–2030)

Table 9: Grade-specific Incident Cases of Oral Mucositis in the 7MM (2018–2030)

Table 10: Total Treated Cases of Oral Mucositis in the 7MM (2018–2030)

Table 11: Total Incident Cases of Oral Mucositis in the United States (2018–2030)

Table 12: Grade-specific Incident Cases of Oral Mucositis in the United States (2018–2030)

Table 13: Treated Cases of Oral Mucositis in the United States (2018–2030)

Table 14: Total Incident Cases of Oral Mucositis in Germany (2018–2030)

Table 15: Grade-specific Incident Cases of Oral Mucositis in Germany (2018–2030)

Table 16: Treated Cases of Oral Mucositis in Germany (2018–2030)

Table 17: Total Incident Cases of Oral Mucositis in France (2018–2030)

Table 18: Grade-specific Incident Cases of Oral Mucositis in France (2018–2030)

Table 19: Treated Cases of Oral Mucositis in France (2018–2030)

Table 20: Total Incident Cases of Oral Mucositis in Italy (2018–2030)

Table 21: Grade-specific Incident Cases of Oral Mucositis in Italy (2018–2030)

Table 22: Treated Cases of Oral Mucositis in Italy (2018–2030)

Table 23: Total Incident Cases of Oral Mucositis in Spain (2018–2030)

Table 24: Grade-specific Incident Cases of Oral Mucositis in Spain (2018–2030)

Table 25: Treated Cases of Oral Mucositis in Spain (2018–2030)

Table 26: Total Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Table 27: Grade-specific Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Table 28: Treated Cases of Oral Mucositis in the United Kingdom (2018–2030)

Table 29: Total Incident Cases of Oral Mucositis in Japan (2018–2030)

Table 30: Grade-specific Incident Cases of Oral Mucositis in Japan (2018–2030)

Table 31: Treated Cases of Oral Mucositis in Japan (2018–2030)

Table 32: Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology Clinical Practice Guidelines for Oral Mucositis

Table 33: ESMO Clinical Practice Guidelines

Table 34: Mouthcare for children and young people with cancer

Table 35: Routine recommended oral care

Table 36: Chemo Mouthpiece, Clinical Trial Description, 2021

Table 37: Brilacidin; Clinical Trial Description, 2021

Table 38: EC-18; Clinical Trial Description, 2021

Table 39: Cooral System; Clinical Trial Description, 2021

Table 40: CareMin650; Clinical Trial Description, 2021

Table 41: Validive (Clonidine Lauriad); Clinical Trial Description, 2021

Table 42: MuReva Phototherapy System; Clinical Trial Description, 2021

Table 43: RRx-001; Clinical Trial Description, 2021

Table 44: SGX942, Clinical Trial Description, 2021

Table 45: Avasopasem(GC4419), Clinical Trial Description, 2021

Table 46: 7MM Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 47: 7MM Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 48: The United States Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 49: The United States Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 50: Germany Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 51: Germany Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 52: France Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 53: France Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 54: Italy Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 55: Italy Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 56: Spain Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 57: Spain Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 58: The United Kingdom Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 59: The United Kingdom Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 60: Japan Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 61: Japan Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)